STEM CELL TREATMENT Dr. Mancao, Chairman Training Committee of PSSCM in PTV Special Forum (Part 3) Please like the official Facebook page of Philippine Medical Association https://www.facebook.com/PhilippineMedicalAssociation STEM CELL TREATMENT - PTV Spec... By: PhilMedAssociation … Continue reading →

Glenmark Generics Limited confirms that it has filed Abbreviated New Drug Applications (ANDAs) for Lacosamide Tablets, and Oral Solution with the U.S. Food and Drug Administration (FDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmarks ANDA products are generic versions of VIMPAT, which are indicated for an adjunctive therapy in the treatment for partial-onset seizures in adults with epilepsy. UCB, INC., UCS Pharma GmbH, Research Corporation Technologies, Inc. and Harris FRC Corporation filed suit against Glenmark Generics Limited and Glenmark Generics Inc. on July 10, 2013, in the United States District Court for the District of Delaware, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of U.S. Patent No.RE 38,551. This lawsuit was filed under the provisions of the Hatch-Waxman Act. If Glenmark is successful in its challenge of the patent, it will garner 180-day exclusivity for its products. According to the IMS health data for the twelve months ending 31 March 2013, VIMPAT tablets and Solution had total U.S. sales of approximately $353 mn. See the rest here: Glenmark Pharma confirms patent challenge for VIPMAT … Continue reading →

Mumbai, July 12: Belgium-based drug maker UCB has challenged Glenmarks attempt to sell its generic version of Vimpat, used in the treatment of epilepsy, in the US. The legal suit followed Glenmarks filing in the US seeking regulatory approvals to sell its generically-similar version of the UCB drug. The filing was a patent challenge, or a para IV filing. Confirming the development, Glenmark said that UCB filed a suit against Glenmark Generics Ltd and Glenmark Generics Inc on July 10, in the United States District Court (Delaware), seeking to prevent Glenmark from commercialising its generic product prior to the expiration of UCBs patent in the US. If Glenmark succeeds in its patent challenge, it would get a 180-day exclusivity for its products. According to foreign media reports, UCB has challenged at least 13 other generic drug-makers over this drug. Industry estimates Vimpat tablets and solution to have annual US sales of about $353 million. (This article was published on July 12, 2013) Continued here: Glenmark confirms patent challenge … Continue reading →

TORONTO Kaitlyn Pogson is a bubbly, giggly, blue-eyed, blonde-haired baby girl. While she looks like a typical baby, her parents know that as she gets older, shell regress, facing developmental and cognitive delays because of a rare form of infant epilepsy called Dravet Syndrome. Its described as potentially fatal the young victims have seizures frequently and for extended periods of time. Last Tuesday, for example, on what was any other day at home, Kaitlyn had an hour-long episode. You feel helpless all you can do is stand and watch, theres nothing you can do to help your child, Kaitlyns father, Barry, told Global News. Sometimes seizures are so strong, Kaitlyns parents take her to hospital. The 19-pound baby could be asleep and recovering for days because she receives heavy doses of medication to interrupt the seizures. Dravet Syndrome, also known as severe myoclonic epilepsy of infancy, usually appears in infants as early as one year old. Babies will encounter a seizure for Kaitlyn, it happened at two months and the frequency of seizures quickly escalates. Dravet syndrome is one of the bad forms of epilepsy, Dr. Berge Minassian, of Torontos Hospital for Sick Children, said. Its genetic, but its not … Continue reading →

The author has posted comments on this articleAgencies | Jul 13, 2013, 06.04AM IST NEW DELHI: Glenmark Pharmaceuticals on Friday said its applications for generic version of epilepsy treatment drug Vimpat in America have been challenged by UCB Inc and other companies in a US court. "UCB Inc, UCS Pharma GmbH, Research Corporation Technologies Inc and Harris FRC Corporation filed suit against Glenmark Generics and Glenmark Generics Inc on July 10, 2013 in the US District Court of Delaware seeking to prevent Glenmark from commercialising its ANDAs prior to expiration of the US Patent No RE 38,551," Glenmark said in a filing to BSE. The company's subsidiary Glenmark Generics had filed the abbreviated new drug applications (ANDAs) for Lacosamide tablets and oral solution with US Food and Drug Administration (USFDA) with a Paragraph IV certification, Glenmark said. "If Glenmark is successful in its challenge of the patent, it will garner 180 days exclusivity for its products," it added. According to IMS Health data for the 12 months ending March 31, 2013 Vimpat tablets and solution had total US sales of $353 million, Glenamrk said. Vimpat is indicated for an adjunctive therapy in the treatment of partial-onset seizures in adults with … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just … Continue reading →

The Lancet Neurology, Early Online Publication, 12 July 2013 Copyright 2013Elsevier LtdAll rights reserved. Findings from randomised trials have shown a higher early risk of stroke after carotid artery stenting than after carotid endarterectomy. We assessed whether white-matter lesions affect the perioperative risk of stroke in patients treated with carotid artery stenting versus carotid endarterectomy. 1036 patients (536 randomly allocated to carotid artery stenting, 500 to carotid endarterectomy) had baseline imaging available. Median ARWMC score was 7, and patients were dichotomised into those with a score of 7 or more and those with a score of less than 7. In patients treated with carotid artery stenting, those with an ARWMC score of 7 or more had an increased risk of stroke compared with those with a score of less than 7 (HR for any stroke 276, 95% CI 117651; p=0021; HR for non-disabling stroke 300, 110836; p=0031), but we did not see a similar association in patients treated with carotid endarterectomy (HR for any stroke 118, 040355; p=076; HR for disabling or fatal stroke 141, 038526; p=0607). Carotid artery stenting was associated with a higher risk of stroke compared with carotid endarterectomy in patients with an ARWMC score of 7 … Continue reading →